On May 16, 2023, Ensoma, Inc. closed the transaction. The company has amended the terms of the transaction. The company now raised $135,000,000 in the transaction.

The company raised $50,000,000 in its final tranche. The tranche included participation from new investors Kite Pharma, Inc., Bioluminescence Ventures and Delos Capital Management, LP and returning investor SymBiosis Capital Management LLC. Kouki Harasaki of Bioluminescence Ventures will join board of directors as a part of the transaction.

The company has raised $129,000,467 pursuant to Regulation D from 22 investors.